Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIA Combination for Epithelioid Sarcoma
NCT05656222Withdrawn
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and vincristine sulfate liposome injection in epithelioid sarcoma (ES), sponsored by Peking University People's Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Aug 2021; status: withdrawn.
02
Drugs
anlotinibirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabvincristine sulfate liposome injection
03
Conditions
epithelioid sarcoma (ES)
Beyond the preview
Go deeper on NCT05656222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656222.